Photodermatology, photoimmunology & photomedicine · 2010
Clinical efficacy of a 308 nm excimer laser in the treatment of vitiligo.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xiu-Ying, He Yan-Ling, Dong Jie, Xu Jun-Zhu, Wang Jie
Аннотация
OBJECTIVE: To investigate the clinical efficacy and safety of the treatment of vitiligo using a 308 nm excimer laser.
METHOD: Thirty-six patients with 44 vitiligo patches were treated using a 308 nm excimer laser, which was performed twice a week, for a total of 30 treatments. The therapeutic efficacy and safety were then evaluated.
RESULTS: After 30 treatments: (1) 27/44 patches (61.4%) achieved more than 75% repigmentation, 4/44 lesions (9.1%) showed 51-75% repigmentation, 10/44 (22.7%) showed 26-50% repigmentation and 3/44 (6.8%) showed 1-25% repigmentation. (2) Of the 44 patches of vitiligo, 20/27 (74.1%) lesions on the face/neck, 9/9 (100%) on the trunk and 2/8 (25.0%) on the extremities showed >or=50% repigmentation. The repigmentation (>or=50%) in face/neck and trunk were much higher than that in the extremities (P<0.05). (3) The repigmentation (>or=50%) in disease duration of <or=2 years and >2 years were 100.0% and 46.2% (P<0.05). (4) The average cumulative doses in the face/neck, trunk and extremities were 7.92+/-5.26, 9.93+/-7.36 and 22.13+/-8.15 J/cm(2). The doses in the face/neck and trunk were much lower than those in the extremities. (P<0.05). Side effects were limited mainly to symptomatic erythema.
CONCLUSION: The clinical data indicate that the treatment of vitiligo using a 308 nm excimer laser is safe and effective. However, lesion location and disease duration may be the key factors affecting the clinical outcome.
METHOD: Thirty-six patients with 44 vitiligo patches were treated using a 308 nm excimer laser, which was performed twice a week, for a total of 30 treatments. The therapeutic efficacy and safety were then evaluated.
RESULTS: After 30 treatments: (1) 27/44 patches (61.4%) achieved more than 75% repigmentation, 4/44 lesions (9.1%) showed 51-75% repigmentation, 10/44 (22.7%) showed 26-50% repigmentation and 3/44 (6.8%) showed 1-25% repigmentation. (2) Of the 44 patches of vitiligo, 20/27 (74.1%) lesions on the face/neck, 9/9 (100%) on the trunk and 2/8 (25.0%) on the extremities showed >or=50% repigmentation. The repigmentation (>or=50%) in face/neck and trunk were much higher than that in the extremities (P<0.05). (3) The repigmentation (>or=50%) in disease duration of <or=2 years and >2 years were 100.0% and 46.2% (P<0.05). (4) The average cumulative doses in the face/neck, trunk and extremities were 7.92+/-5.26, 9.93+/-7.36 and 22.13+/-8.15 J/cm(2). The doses in the face/neck and trunk were much lower than those in the extremities. (P<0.05). Side effects were limited mainly to symptomatic erythema.
CONCLUSION: The clinical data indicate that the treatment of vitiligo using a 308 nm excimer laser is safe and effective. However, lesion location and disease duration may be the key factors affecting the clinical outcome.